Financial Performance - Elutia divested its cardiac implantable electronic device (CIED) product family for an aggregate purchase price of up to $88.0 million in cash, with $80.4 million received at closing[26]. - The sale of the CIED business resulted in a net gain of $76.1 million for Elutia in 2025[32]. - The company reported losses from continuing operations of $26.9 million and $30.7 million for the years ended December 31, 2025, and 2024, respectively, and expects losses to continue for the foreseeable future[139]. - The company completed the sale of its cardiac implantable electronic device (CIED) business on October 1, 2025, which may impact future financial contributions[135]. - The sale of the Orthobiologics Business generated approximately $14.6 million, with potential additional earn-out payments of up to $20.0 million[34]. - The sale of the Orthobiologics Business to Berkeley on November 8, 2023, resulted in an initial payment of $14.6 million, with potential additional earn-out payments of up to $20.0 million based on future revenues[166]. - Future capital needs are uncertain, and the company may need to raise additional funds through equity offerings or debt financings, which could dilute existing shareholders[150]. Market Opportunities - The U.S. market opportunity for Elutia's next-generation antibiotic-eluting biomatrix products is estimated to be approximately $1.5 billion[42]. - The estimated U.S. market opportunity for biologic matrices is approximately $1.5 billion, accounting for over 60% of reconstruction spending[75]. - EluPro, the first antibiotic-eluting biologic matrix envelope, achieved annualized revenues of approximately $19 million, with EluPro contributing about $14 million[41]. Product Development - Elutia's lead development programs include NXT-41 and NXT-41x, aimed at addressing complications in reconstructive procedures, with a focus on local antibiotic drug delivery[28]. - The NXT-41 and NXT-41x development programs are expected to receive FDA clearance in the second half of 2026 and mid-2027, respectively[77]. - The company is focusing on the development of NXT-41x, a biomatrix aimed at improving interactions between implanted medical devices and patients, which will require significant investments[136]. Regulatory Environment - The company’s products are subject to extensive regulation by the FDA and other authorities, ensuring safety and effectiveness for intended uses[89]. - Medical devices are classified into three categories based on risk, with Class I devices being low-risk and usually exempt from premarket notification, while Class III devices require more rigorous PMA approval[90]. - The 510(k) clearance process typically takes three to twelve months, but may extend longer if additional information is required by the FDA[93]. - Significant modifications to a device after 510(k) clearance necessitate a new clearance or PMA approval, with non-compliance potentially leading to regulatory fines[94]. - The PMA process requires extensive pre-clinical and clinical data, with FDA having 180 days for review, often extending beyond this period[95]. - Clinical studies must adhere to FDA's IDE regulations, requiring approval from an Institutional Review Board (IRB) at each site[98]. - Post-market regulations include mandatory reporting of device-related incidents and compliance with quality management system requirements[101]. Competitive Landscape - SimpliDerm competes against products like AbbVie's AlloDerm and various synthetic mesh products in the soft tissue repair market[63]. - The company faces significant competition from established firms with greater resources, which could hinder market penetration and operating results[185]. - Pricing pressure from cost-containment efforts by customers and third-party payors could adversely affect sales and profitability[189]. - The healthcare industry is experiencing consolidation trends, which may exert downward pressure on product prices and affect sales volumes[193]. Legal and Liability Risks - The company has recorded a total estimated contingent liability of $11.2 million related to lawsuits from the FiberCel and Viable Bone Matrix recalls, with $6.8 million for FiberCel and $4.4 million for VBM as of December 31, 2025[141]. - As of December 31, 2025, the company has no insurance coverage for the FiberCel recall liability, which poses a significant financial risk[142]. - The company faces ongoing litigation related to the FiberCel and VBM recalls, with 110 separate lawsuits or claims received since September 2021[143]. - Warranty claims and product recalls could result in significant costs and negatively affect the company's financial condition[207][212]. - The company may face significant legal costs and liabilities due to product liability claims, which could adversely affect its cash flow and financial position[149]. Operational Challenges - The company relies on a limited number of suppliers, including a single supplier for SIS ECM biomaterial, which poses risks of significant product development costs and delivery delays[168]. - The company relies on independent sales agents for generating Women's Health and Cardiovascular sales, which poses risks related to customer relationships and sales performance[173]. - The company must manage growth effectively to penetrate and service existing and future markets, which may strain operational and financial resources[184]. - Shipping performance issues, including delays and increased rates, could adversely affect the company's operating margins and results[194]. - Increased prices for raw materials and supplies could negatively impact the company's profitability and financial condition[196][197]. - The company may struggle to pass on cost increases to customers, potentially leading to lower margins and profitability[198]. - Inaccurate demand forecasting and inventory management could result in lost sales and decreased margins, adversely affecting financial results[199]. - The company faces risks of inventory obsolescence due to the shelf life of products, which could lead to material adverse effects on profitability[200]. Human Resources and Workplace Culture - The company is committed to fostering an equitable and inclusive workplace, which is essential for attracting and retaining qualified personnel[128]. - The company aims to offer competitive pay and benefits to attract and retain exceptional talent, including an annual cash incentive program and long-term equity incentive plans[129]. - The company may experience challenges in attracting and retaining skilled personnel due to intense competition in the healthcare industry[224]. - Retaining key management personnel is essential for navigating business challenges and achieving growth objectives[224]. Cybersecurity Risks - Company faces increasing risks from cyberattacks, with sophisticated groups targeting sensitive data and IT systems[218]. - Potential financial impacts from unauthorized access or data breaches could lead to legal claims and damage to reputation[221]. - Cybersecurity insurance may not cover all claims, which could adversely affect financial condition if large claims arise[223]. - The evolving nature of cyber threats complicates prevention and detection efforts, increasing operational risks[218].

Financial Results - Elutia Inc. announced preliminary results for Q4 2025, with results subject to year-end accounting and audit procedures[4] - The press release detailing the financial results was issued on January 12, 2026[4] Company Information - The company is listed on The Nasdaq Capital Market under the trading symbol ELUT[2]

Financial Performance - Net sales for the three months ended September 30, 2025, were $3,323,000, down 9.2% from $3,662,000 in the same period of 2024[29]. - Gross profit for the three months ended September 30, 2025, was $1,853,000, compared to $1,791,000 for the same period in 2024, reflecting a slight increase of 3.5%[29]. - The net loss attributable to common stockholders for the three months ended September 30, 2025, was $3,868,000, compared to a net income of $1,067,000 in the same period of 2024[29]. - For the nine months ended September 30, 2025, the net loss was $17.4 million, compared to a net loss of $44.9 million for the same period in 2024, indicating a significant improvement[34]. - For the nine months ended September 30, 2025, the net loss was $8,050,000 compared to a net loss of $6,878,000 for the same period in 2024[93]. - The company reported a loss from operations of $5,208,000 for the three months ended September 30, 2025, compared to a loss of $9,175,000 in the same period of 2024[29]. - Loss from operations improved by 43.2% to $(5.2) million in Q3 2025 compared to $(9.2) million in Q3 2024[197]. Assets and Liabilities - Total current assets decreased from $26,172,000 as of December 31, 2024, to $18,378,000 as of September 30, 2025, a decline of approximately 29.7%[27]. - Cash and cash equivalents decreased from $13,239,000 as of December 31, 2024, to $4,721,000 as of September 30, 2025, a decline of approximately 64.3%[27]. - The total liabilities increased from $82,387,000 as of December 31, 2024, to $73,325,000 as of September 30, 2025, a decrease of approximately 11%[27]. - The company’s total stockholders' equity (deficit) as of September 30, 2025, was $(43.9) million, compared to $(40.2) million as of September 30, 2024[34]. Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $7,061,000, a decrease of 35.5% from $10,966,000 in the prior year[29]. - Stock-based compensation for the nine months ended September 30, 2025, was $4.3 million, down from $6.7 million in the same period of 2024[34]. - General and administrative expenses decreased by 18.9% to $3.5 million in Q3 2025, primarily due to lower non-cash equity compensation[202]. - Total operating expenses decreased by $3.6 million, or 12.6%, to $25.0 million for the nine months ended September 30, 2025, compared to $28.6 million for the same period in 2024[208]. Research and Development - Research and development expenses increased to $1,088,000 for the three months ended September 30, 2025, from $702,000 in the same period of 2024, an increase of 55%[29]. - The company is aggressively pursuing the development of NXT-41 and NXT-41x, next-generation biologic scaffolds combined with local antibiotic delivery, reflecting heightened R&D activity[215]. - R&D expenses increased by $0.4 million, or 55.0%, to $1.1 million for the three months ended September 30, 2025, compared to $0.7 million for the same period in 2024[203]. Cash Flow and Financing - The company experienced a cash outflow of $20 million from operating activities for the nine months ended September 30, 2025, compared to $10.4 million in the prior year[34]. - The company anticipates using its new facility in Gaithersburg, Maryland for commercial production of new products, pending marketing authorization[68]. - The company may seek to raise additional capital through equity issuance or asset sales to finance operations[49]. - The company expects to incur operating losses and negative cash flows from operations for the foreseeable future as it advances the development and commercialization of NXT-41 and NXT-41x[224]. Discontinued Operations - The company completed the sale of its cardiac implantable electronic device (CIED) business for up to $88 million, with $80.3 million received at closing[42][44]. - The sale of the CIED business is classified as discontinued operations, significantly impacting the company's financial results[45]. - The divestiture of the CIED Business was completed on October 1, 2025, with related assets and liabilities classified as discontinued operations[95]. - The sale of the Orthobiologics Business generated $14.6 million, with potential additional earn-out payments of up to $20 million based on future sales[186]. Litigation and Legal Matters - As of September 30, 2025, there were 44 active lawsuits related to FiberCel, with 38 settlements reached but not yet paid[140]. - The company is involved in ongoing litigation against Medtronic regarding breach of the Tissue Product Supply Agreement, with discovery still ongoing[141]. - The total cash outlay for settled cases in the FiberCel Litigation amounted to $22.5 million, with $9.6 million covered by insurance proceeds[144]. - The Company recorded a total cash outlay of approximately $1.5 million for settled cases in the VBM Litigation, with an estimated liability of $3.7 million for the remaining cases as of September 30, 2025[148]. Market and Sales - The estimated U.S. market for biologic matrices is $1.5 billion, accounting for over 60% of reconstruction spending[172]. - The company continues to market SimpliDerm, a human-derived acellular dermal matrix, which is a key component of the Women's Health segment[168]. - The net sales for Women's Health for the nine months ended September 30, 2025, were $7.015 million, while Cardiovascular net sales were $2.007 million, totaling $9.022 million[162]. - The company has experienced seasonality in sales, with higher sales typically in the fourth quarter due to hospital purchasing patterns[223].

Financial Performance - Overall net sales for Q3 2025 were $3.3 million, a decrease from $3.7 million in Q3 2024, excluding contributions from the BioEnvelope business[5] - Net sales of SimpliDerm were $2.4 million in Q3 2025, down from $3.1 million in Q3 2024[5] - Net sales for Q3 2025 were $3,323 million, a decrease of 9.2% compared to $3,662 million in Q3 2024[17] - The net loss for Q3 2025 was $3,868 million, compared to a net income of $1,286 million in Q3 2024[20] - Elutia's adjusted EBITDA for Q3 2025 was a loss of $2.7 million, approximately the same as the previous year[10] - Adjusted EBITDA for Q3 2025 was $(2,742) million, slightly worse than $(2,682) million in Q3 2024[20] Cost Management and Expenses - Total operating expenses decreased to $7.1 million in Q3 2025, down from $11.0 million in the same period last year[10] - Total operating expenses for Q3 2025 were $7,061 million, down from $10,966 million in Q3 2024, primarily due to reduced litigation costs[17] - Research and development expenses increased to $1,088 million in Q3 2025 from $702 million in Q3 2024, reflecting a focus on innovation[17] Profitability Metrics - Gross margin on a GAAP basis improved to 55.8% in Q3 2025, compared to 48.9% in Q3 2024[10] - Gross profit for Q3 2025 was $1,853 million, representing a gross margin of 55.8%, up from 48.9% in Q3 2024[18] - The adjusted gross profit for Q3 2025 was $2,122 million, with an adjusted gross margin of 63.9%, up from 56.3% in Q3 2024[18] Strategic Actions - Elutia sold its BioEnvelope business to Boston Scientific Corporation for $88 million, with proceeds used to eliminate debt and fund the NXT-41x development program[4] - The anticipated FDA clearance for the base matrix of NXT-41x is expected in the second half of 2026, with the drug-eluting version expected in the first half of 2027[4] - The company has resolved a significant portion of its legacy litigation, leaving only six cases unresolved, which is expected to reduce future litigation expenses[4] - The company anticipates continued focus on cost management and strategic investments in R&D to drive future growth[21] Operational Losses - Loss from operations was $5.2 million in Q3 2025, an improvement from a loss of $9.2 million in Q3 2024[10] - The company reported a loss from discontinued operations of $3,485 million in Q3 2025, compared to $2,053 million in Q3 2024[20] Shareholder Information - The weighted average common shares outstanding for basic shares increased to 42,431,314 in Q3 2025 from 32,520,134 in Q3 2024[17]

Financial Performance - For the three months ended June 30, 2025, net sales were $6,263,000, a slight decrease of 0.4% compared to $6,291,000 for the same period in 2024[29]. - Gross profit for the six months ended June 30, 2025, was $5,515,000, compared to $5,642,000 for the same period in 2024, reflecting a decrease of 2.3%[29]. - The net loss for the three months ended June 30, 2025, was $9,610,000, significantly improved from a net loss of $28,180,000 for the same period in 2024[29]. - For the six months ended June 30, 2025, the company reported a net loss of $13.5 million, a significant improvement from a net loss of $46.2 million in the same period of 2024, representing a reduction of approximately 70.8%[34]. - The net loss from continuing operations for the three months ended June 30, 2025, was $9,610 million, compared to a loss of $28.360 million for the same period in 2024[136]. Cash Flow and Liquidity - The company used $17.1 million in cash for operating activities during the first half of 2025, compared to $7.0 million in the same period of 2024, indicating increased cash outflows[34]. - Cash and cash equivalents at the end of the period were $8.5 million, down from $18.2 million at the end of June 2024, reflecting a decrease of 53.3%[34]. - The company anticipates continued losses in the foreseeable future, impacting its financial position and profitability[204]. - The company may seek to raise capital through equity or debt securities to address liquidity issues, with substantial doubt about its ability to continue as a going concern within one year after the issuance of the financial statements[205]. Assets and Liabilities - Total current assets decreased to $22,280,000 as of June 30, 2025, down from $26,172,000 as of December 31, 2024, representing a decline of 15%[27]. - Total liabilities increased to $75,692,000 as of June 30, 2025, compared to $82,387,000 as of December 31, 2024, indicating a reduction of 8.1%[27]. - The accumulated deficit increased to $243,136,000 as of June 30, 2025, from $229,593,000 as of December 31, 2024[27]. - The total stockholders' deficit improved to $41,843,000 as of June 30, 2025, compared to $46,260,000 as of December 31, 2024[27]. Research and Development - Research and development expenses for the three months ended June 30, 2025, were $1,456,000, an increase of 45.5% compared to $1,001,000 for the same period in 2024[29]. - R&D expenses increased to $2.4 million for the six months ended June 30, 2025, reflecting heightened development activity, including expanding the EluPro offering[191]. Stock and Compensation - The company reported stock-based compensation expenses of $2.4 million for the six months ended June 30, 2025, down from $4.9 million in the same period of 2024[34]. - The Company has approximately $2.5 million of total unrecognized compensation expense related to unvested stock options, expected to be recognized over a weighted-average period of 1.4 years[84]. - The Company had 1,167,991 unvested Restricted Stock Units (RSUs) as of June 30, 2025, with a weighted average fair value of $3.45 per share[88]. Litigation and Legal Matters - The Company has 47 active lawsuits related to FiberCel, with settlements reached in 34 cases but not yet paid as of June 30, 2025[123]. - Elutia has settled liabilities in 63 cases of the FiberCel Litigation for a total cash outlay of $21.5 million, with $9.6 million covered by insurance proceeds[127]. - The estimated probable loss for the remaining 47 FiberCel cases is $13.3 million, which includes $11.1 million for settlements reached but not yet paid[128]. Sales and Market Segments - The Company operates in three segments: Device Protection, Women's Health, and Cardiovascular, following the divestiture of the Orthobiologics Business in 2023[139]. - Device Protection sales increased by $0.9 million to $3.516 million, representing a growth of 33.2%, while Women's Health and Cardiovascular sales declined by 21.8% and 31.9%, respectively[175]. - The company anticipates future growth in Cardiovascular sales through volume growth and higher unit prices following the termination of the exclusive distribution agreement[176]. Debt and Financing - The company raised approximately $15.0 million in gross proceeds from the 2025 Registered Offering, selling 5,520,000 shares of Class A common stock at $2.50 per share[109][110]. - The SWK Loan Facility matures on August 10, 2027, with principal payments commencing on November 15, 2025, at a rate of 5% of the outstanding principal[217]. - The company entered into an amendment to the SWK Loan Facility in May 2025, allowing for 100% of the interest payment to be paid as PIK interest and fixing the Liquidity Covenant to a minimum of $8.0 million[220].

Revenue and Sales Performance - EluPro revenue increased by 49% sequentially in Q2 2025, contributing approximately two-thirds of total BioEnvelope sales, which reached $3.5 million, a 33% year-over-year increase[5] - The customer base for EluPro has grown more than 15 times since its launch, with over 160 VAC-approved hospitals now using the product[5] - Average sales per EluPro customer were 130% higher than for CanGaroo customers, indicating stronger procedure penetration[5] - The company expects BioEnvelope sales to approach a $20 million annualized run rate by year-end 2025[4] - Overall net sales for Q2 2025 were $6.3 million, consistent with Q2 2024, while net loss decreased to $9.6 million from $28.2 million[8] - Net sales for Q2 2025 were $6,263 million, a slight decrease of 0.4% compared to $6,291 million in Q2 2024[15] - Gross profit for Q2 2025 increased to $3,058 million, up 9.2% from $2,799 million in Q2 2024[15] - Adjusted gross profit (Non-GAAP) for Q2 2025 was $3,907 million, representing a 7.1% increase from $3,648 million in Q2 2024[16] Operating Expenses and Financial Metrics - Total operating expenses increased to $12.9 million in Q2 2025, compared to $11.3 million in the same period last year[8] - Total operating expenses for Q2 2025 were $12,933 million, an increase of 14.3% compared to $11,309 million in Q2 2024[15] - Adjusted EBITDA (Non-GAAP) for Q2 2025 was $(3,829) million, worsening from $(2,648) million in Q2 2024[18] - Net loss for Q2 2025 was $9,610 million, a significant improvement from a net loss of $28,180 million in Q2 2024[18] - Net loss per share (basic) for Q2 2025 was $(0.23), compared to $(1.13) in Q2 2024[15] - Cash balance as of June 30, 2025, was $8.5 million, down from $13.2 million at the end of 2024[13] Litigation and Legal Matters - The company has settled 97 of 110 FiberCel litigation cases, significantly reducing expected litigation expenses going forward[5] - Litigation costs for Q2 2025 were $4,004 million, significantly higher than $2,289 million in Q2 2024[18] Product Development and Market Strategy - Elutia is advancing its NXT-41 platform for breast reconstruction, targeting FDA clearance of the base matrix in 2H26 and the drug-eluting version in 1H27, addressing a $1.5 billion market[4] - Adjusted gross margin improved to 62.4% in Q2 2025, up from 58.0% in Q2 2024[8] - Gross margin for Q2 2025 improved to 48.8%, up from 44.5% in Q2 2024[16] - Weighted average common shares outstanding (diluted) increased to 46,308,642 in Q2 2025 from 24,900,167 in Q2 2024[15]

Financial Performance - Net sales for Q1 2025 were $6,030,000, a decrease of 9.9% compared to $6,694,000 in Q1 2024[29] - Gross profit for Q1 2025 was $2,457,000, down from $2,843,000 in Q1 2024, reflecting a gross margin of 40.7%[29] - The net loss for Q1 2025 was $3,933,000, significantly improved from a net loss of $17,994,000 in Q1 2024[29] - The company reported a loss from operations of $7,922,000 for Q1 2025, slightly improved from a loss of $8,479,000 in Q1 2024[29] - For the three months ended March 31, 2025, the company reported a net loss of $3.93 million, compared to a net loss of $17.99 million for the same period in 2024[135] - The company’s segment gross profit for the three months ended March 31, 2025, was $3.31 million, down from $3.69 million in the same period of 2024[138][139] - Loss before provision for income taxes improved to $(3,925,000) in Q1 2025 from $(17,986,000) in Q1 2024, representing a reduction of 78.2%[140] Assets and Liabilities - Total current assets increased to $30,017,000 as of March 31, 2025, compared to $26,172,000 as of December 31, 2024, representing a 10.8% increase[27] - Total liabilities decreased to $75,756,000 as of March 31, 2025, down from $82,387,000 as of December 31, 2024, a reduction of 8.1%[27] - Long-term debt as of March 31, 2025, was $21,762,000, a decrease from $22,603,000 as of December 31, 2024[105] - The company had cash of approximately $17.4 million as of March 31, 2025, with an accumulated deficit of $233.5 million[183] - As of March 31, 2025, the company had $24.3 million of total indebtedness, including $23.8 million under the SWK Loan Facility[197] Cash Flow and Financing - The Company used $8.9 million of cash in operating activities during the same period and expects continued cash outflows throughout 2025[44] - For the three months ended March 31, 2025, net cash used in operating activities was $8.9 million, an increase from $2.6 million in the same period in 2024, primarily due to higher trade obligations and FiberCel settlement payments of $3.0 million[193] - The company reported net cash provided by financing activities of $13.3 million for the three months ended March 31, 2025, compared to cash used of $4.1 million in the same period in 2024, mainly due to the 2025 Registered Offering[196] - The company raised approximately $15.0 million in gross proceeds from a registered direct offering on February 4, 2025, selling 5,520,000 shares of Class A common stock[110] - The company raised $2.2 million in outstanding royalty obligations to Ligand by issuing 1,105,528 shares of Class A common stock[210] Research and Development - Research and development expenses for Q1 2025 were $905,000, down from $1,172,000 in Q1 2024, indicating a 22.8% reduction[29] - Research and development costs are expensed as incurred, primarily consisting of salaries, outside services, and supplies[77] - Research and development expenses primarily focus on expanding the EluPro product line and developing new DEB products[163] Litigation and Contingencies - The company has settled liabilities in 52 cases of the FiberCel Litigation for a total cash outlay of $17.5 million, with an estimated probable loss of $14.3 million recorded for the remaining cases as of March 31, 2025[126] - As of March 31, 2025, there were 58 active lawsuits related to FiberCel, with 18 settlements reached but not yet paid[122] - The company has a contingent liability of $3.6 million related to the VBM Litigation as of March 31, 2025[129] - The company has recorded insurance receivables of $3.9 million related to litigation costs as of March 31, 2025[132] - Litigation costs increased to $2.6 million in Q1 2025 from $1.8 million in Q1 2024, primarily due to the lack of insurance coverage for certain litigation costs[174] Going Concern and Capital Needs - The Company has substantial doubt about its ability to continue as a going concern within one year from the issuance of the financial statements due to liquidity issues[45] - There is substantial doubt about the company's ability to continue as a going concern within one year after the issuance of the financial statements due to liquidity uncertainties[190] - The company may need additional funds sooner than anticipated, leading to potential dilution of ownership interests if additional capital is raised through equity or convertible debt securities[214] Inventory and Revenue Recognition - The Company evaluates its inventory for excess quantities and obsolescence, adjusting carrying values as necessary[60] - The Company recognizes revenue when control of products transfers to customers, primarily upon shipment or delivery[70] - A portion of the Company's product revenue comes from consigned inventory, with revenue recognized when the product is used or implanted[71] - As of March 31, 2025, the Company had total inventory of $4.286 million, an increase from $3.911 million as of December 31, 2024[98] Stock and Compensation - The weighted average common shares outstanding for diluted earnings per share increased to 42,913,111 in Q1 2025 from 23,912,326 in Q1 2024[29] - The Company reported a total stock-based compensation expense of $1.211 million for the three months ended March 31, 2025, a decrease of 44.8% compared to $2.197 million for the same period in 2024[97] - The Company had 3,204,215 stock options outstanding as of March 31, 2025, with a weighted average exercise price of $5.23 and an aggregate intrinsic value of $22,000[88] - The Company had 1,342,766 unvested restricted stock units (RSUs) as of March 31, 2025, with a weighted average grant date fair value of $3.49[92] - The Company had approximately $2.7 million of total unrecognized compensation expense related to unvested stock options expected to be recognized over a weighted-average period of 1.7 years[88] - The Company had $3.9 million of unrecognized compensation costs related to RSUs expected to be recognized over a weighted average period of 1.8 years[93] Market Risks and Accounting Policies - The company is exposed to various market risks, including interest rate risk, foreign currency risk, and credit risk, which could impact financial performance[220][221][223] - A hypothetical 10% relative change in interest rates on variable rate indebtedness as of March 31, 2025, would not have had a material effect on the financial statements[221] - The company has not experienced material changes in critical accounting policies and estimates during the three months ended March 31, 2025, other than those outlined in Note 2[215] - The company has elected to take advantage of the JOBS Act exemptions, allowing for an extended transition period for adopting new accounting standards[218] - The company will remain an emerging growth company until annual gross revenues reach $1.235 billion or more, or until other specified conditions are met[219] Operational Developments - The Company completed the sale of its Orthobiologics segment to Berkeley Biologics for approximately $14.6 million, with potential earn-out payments of up to $20 million based on future sales[41] - The Company recognized a gain of $6.0 million from the sale of the Orthobiologics Business in Q4 2023 and an additional gain of $0.2 million in Q2 2024[41] - The Company executed a new lease for 26,598 square feet with monthly payments of approximately $75,000, expiring in January 2036[63] - EluPro, the only drug-eluting biomatrix in the U.S. implantable electronic device protection market, was cleared for marketing by the FDA in June 2024[153] - The company expects to commence operations in a new facility in Gaithersburg, Maryland, in Q2 2025, aiming to internally produce components of EluPro by Q4 2025[152] - The company plans to expand its drug-eluting biomatrix (DEB) offerings beyond EluPro to address unmet clinical needs in breast reconstruction and neurostimulation[147][148] - SimpliDerm is marketed through a distribution agreement with Tiger Aesthetics Medical, providing access to approximately 50 sales representatives[150]

Sales Performance - EluPro sales increased by 84% sequentially, contributing to a 31% year-over-year growth in BioEnvelope revenue, totaling $3.1 million, with EluPro accounting for approximately 52% of BioEnvelope sales in the quarter[2] - Overall net sales decreased by 10% to $6.0 million compared to $6.7 million in Q1 2024, with net sales of SimpliDerm at $2.6 million and Cardiovascular products at $0.3 million[6] - Net sales for Q1 2025 were $6,030,000, a decrease of 9.95% compared to $6,694,000 in Q1 2024[14] Financial Metrics - Gross margin on a GAAP basis was 40.7%, down from 42.5% in the previous year, while adjusted gross margin was 54.8%, slightly down from 55.2%[6] - Gross profit for Q1 2025 was $2,457,000, down from $2,843,000 in Q1 2024, resulting in a gross margin of 40.7% compared to 42.5% in the previous year[14] - Adjusted gross profit (Non-GAAP) for Q1 2025 was $3,306,000, a decline from $3,692,000 in Q1 2024, with an adjusted gross margin percentage of 54.8% compared to 55.2%[14] Operating Expenses and Losses - Total operating expenses decreased to $10.4 million from $11.3 million, resulting in a loss from operations of $7.9 million compared to $8.5 million in Q1 2024[6] - The company reported a net loss of $3.9 million for Q1 2025, significantly improved from a net loss of $18.0 million in Q1 2024[13] - The net loss for Q1 2025 was $(3,933,000), significantly improved from a net loss of $(17,994,000) in Q1 2024[16] - EBITDA (Non-GAAP) for Q1 2025 was $(1,972,000), an improvement from $(15,809,000) in Q1 2024[16] - Adjusted EBITDA (Non-GAAP) for Q1 2025 was $(3,271,000), slightly better than $(3,633,000) in Q1 2024[16] Cash and Financing - Cash balance as of March 31, 2025, was $17.4 million, an increase from $13.2 million at the end of 2024[11] - The company raised $15.0 million in gross proceeds through a registered direct offering and amended loan terms to allow full PIK interest, potentially accessing an additional $5 million term loan[2] Strategic Partnerships and Contracts - Elutia signed two new GPO contracts in Q1 2025, bringing total coverage to seven, enhancing market access for EluPro[2] - The partnership with Boston Scientific is expected to accelerate EluPro adoption, with BSC already generating sales in over 50 hospitals[2] Awards and Recognition - EluPro received a 2025 Edison Award for innovation in post-surgical recovery, further validating its market position[2] Other Financial Details - Interest expense for Q1 2025 was $1,085,000, down from $1,313,000 in Q1 2024[16] - Stock-based compensation for Q1 2025 was $1,211,000, compared to $2,197,000 in Q1 2024[16] - Litigation costs for Q1 2025 amounted to $2,572,000, up from $1,785,000 in Q1 2024[16] - The company recorded a gain on revaluation of warrant liability of $(5,187,000) in Q1 2025, compared to a loss of $9,636,000 in Q1 2024[16]

Product Development and Innovation - Elutia's EluPro is the only drug-eluting biomatrix in the U.S. for implantable electronic device protection, addressing complications such as infection and device migration[32][33]. - Elutia's innovative DEB technology is expected to redefine patient outcomes and procedural success in implantable device surgeries[42]. - EluPro received FDA clearance in June 2024, with ongoing stability studies to support a Special 510(k) filing for additional sizes[62]. - Elutia's SimpliDerm product, utilizing human-based hydrated acellular dermal matrix, aims to enhance tissue incorporation and reduce inflammation compared to other matrices[34]. - SimpliDerm is designed to improve biocompatibility and tissue integration, utilizing patented cell removal technology to maintain the extracellular matrix's integrity[90]. - SimpliDermRM is being developed to address post-operative infections in breast reconstruction, which affect over 10% of patients, with complication rates for implant-based reconstruction ranging from 26% to 31%[91][92]. - SimpliDerm's clinical data supports its differentiation in the market, with testing indicating it has a structurally intact matrix closest to native human dermis compared to alternatives[98][99]. Market Opportunities and Strategy - The company estimates over 700,000 surgical procedures annually in the U.S. involve the implantation of medical devices, driven by technological advances and an aging population[28]. - Elutia's growth strategy focuses on increasing penetration in Device Protection and Women's Health markets, which represent a combined market opportunity of over $1 billion in the U.S.[44]. - The commercial approach includes a partnership with Boston Scientific, providing access to approximately 900 sales representatives to expand market penetration[64]. - The use of acellular dermal matrices in breast reconstruction surgery in the U.S. grew by 29% in 2022 compared to 2020, representing a market of approximately $500 million[83]. - The company has established commercial relationships with major medical device companies, leveraging approximately 1,100 sales representatives to enhance market penetration[46]. Financial Performance and Challenges - The company reported net losses of $53.9 million and $37.7 million for the years ended December 31, 2024, and 2023, respectively[187]. - The accumulated deficit as of December 31, 2024, was $229.6 million, raising substantial doubt regarding the company's ability to continue as a going concern[188]. - The company has incurred operating losses and expects to continue doing so in the near term, impacting its financial position[187]. - The company is actively seeking additional funding to support operations and pursue growth strategies, which may include issuing common stock or asset sales[190]. - The company faces significant litigation risks related to product recalls, with 66 lawsuits outstanding for FiberCel Recall and 15 for VBM Recall as of December 31, 2024[204]. Regulatory Environment - The company’s products are subject to extensive regulation by the FDA, with medical devices classified into three categories based on risk, impacting the marketing and approval processes[129][130]. - The FDA can impose sanctions for non-compliance, including product recalls and withdrawal of marketing approvals[142]. - The company no longer maintains its CE mark for cardiovascular products in the EU, which expired on May 23, 2024[146]. - International sales of medical devices require compliance with varying regulatory requirements across different countries[145]. Product Sales and Distribution - Sales in the U.S. accounted for over 96% of the company's net sales in 2024, with international sales ceasing after May 2024 due to regulatory changes[111]. - The company signed a lease for 26,598 square feet in Gaithersburg, Maryland, to develop in-house production capabilities for SimpliDerm, expected to be operational by Q3 2025[116]. - The company has a direct sales force and independent agents, with 11 direct representatives and 31 independent agents focused on expanding market access[37]. Legal and Liability Issues - The company recorded a total estimated contingent liability of $20.4 million related to FiberCel and VBM lawsuits, with $15.9 million for FiberCel and $4.5 million for VBM as of December 31, 2024[200]. - As of December 31, 2024, the company has exhausted its insurance coverage for FiberCel liability, leaving a contingent liability of $15.9 million entirely as its financial responsibility[208]. - The company must maintain a minimum liquidity of $5.0 million or the sum of the operating burn for the two prior consecutive fiscal quarters, as per the financial covenants of the SWK Loan Facility[195]. Operational Risks and Dependencies - The company faces risks related to its reliance on a limited number of third-party suppliers, particularly Cook, which supplies essential biomaterials for its products[226]. - The company has significant expansion capabilities in its in-house manufacturing facility located in Roswell, Georgia, and relies on Cook Biotech as its sole porcine tissue supplier[114]. - The company acknowledges that current volatility in capital and credit markets could impede access to financing, potentially affecting its operational and strategic decisions[216].

Sales Performance - Overall BioEnvelope sales increased by 18%, with same-center sales rising by 65% following the commercialization of EluPro[1] - EluPro accounted for over 30% of BioEnvelope sales in Q4 2024, indicating strong initial market uptake[4] - Net sales for BioEnvelope products totaled $9.9 million for the full year 2024, up from $9.4 million in 2023, reflecting a 5% increase[5] - Net sales of SimpliDerm increased by 12% to $11.6 million compared to $10.3 million in 2023[5] - Net sales for Q4 2024 were $5,468 million, a decrease of 6.9% compared to $5,875 million in Q4 2023[15] Financial Performance - Net loss from continuing operations was $54.1 million for the full year 2024, compared to a loss of $41.2 million in 2023[8] - Cash balance as of December 31, 2024, was $13.2 million, following a registered direct offering that raised approximately $15 million[8] - Adjusted EBITDA for Q4 2024 was a loss of $3.8 million, an improvement from a loss of $4.5 million in Q4 2023[8] - Net loss for Q4 2024 was $9,061 million, compared to a net loss of $9,316 million in Q4 2023, showing a 2.7% improvement[18] - Adjusted EBITDA (Non-GAAP) for Q4 2024 was a loss of $3,751 million, an improvement from a loss of $4,453 million in Q4 2023[18] Operating Expenses - Total operating expenses for Q4 2024 were $10.8 million, slightly up from $10.6 million in Q4 2023[8] - Total operating expenses for Q4 2024 were $10,756 million, slightly up from $10,631 million in Q4 2023[15] - Research and development expenses for Q4 2024 were $834 million, down from $1,381 million in Q4 2023[15] Profitability Metrics - Gross margin on a GAAP basis was 43.9% for the full year 2024, down from 44.7% in 2023[8] - Gross profit for Q4 2024 increased to $2,324 million, up 9.4% from $2,124 million in Q4 2023[15] - Adjusted gross profit (Non-GAAP) for Q4 2024 was $3,175 million, compared to $2,975 million in Q4 2023, reflecting a 6.7% increase[16] - Gross margin for Q4 2024 was 42.5%, up from 36.2% in Q4 2023[16] - Adjusted gross margin percentage (Non-GAAP) for Q4 2024 was 58.1%, compared to 50.6% in Q4 2023[16] Customer Metrics - The company had approximately 100 actively ordering accounts by the end of 2024, with 67 approved EluPro accounts[4] Share Information - Weighted average common shares outstanding for Q4 2024 were 34,845,672, compared to 23,195,190 in Q4 2023[15]